期刊文献+

盐酸苯噁唑在鹿体内的药代动力学研究

Study on Pharmacokinetics of Idazoxan Hydrochloric in Deer
下载PDF
导出
摘要 本研究的主要目的是建立鹿血浆盐酸苯噁唑浓度反相高效液相色谱紫外检测法,探讨盐酸苯噁唑在鹿血浆中的药代动力学。6只临床健康的梅花鹿,同一环境下饲养后肌内注射盐酸苯恶唑(0.44mg.kg-1),颈静脉采血8mL后分离血浆,通过建立的高效液相色谱检测法,测定各采血时间的血浆药物浓度。结果表明,盐酸苯噁唑单剂量肌内注射给药后,药代动力学符合吸收一室模型,药代动力学参数吸收半衰期(t1/2Ka)、消除半衰期(t1/2Ke)分别为(2.09±0.34)、(13.18±0.24)min,血浆药时曲线下面积(AUC0→∞)为(70±3.50)(μg.mL-1).min,最大血药浓度(Cmax)为(4.70±0.50)μg.mL-1,血药达峰时间(Tpeak)为(12.46±0.12)min。试验结果提示,盐酸苯噁唑在鹿体内吸收快,消除迅速,4h后血浆中无药物残留。 This experiment was to establish a method for the determination of idazoxan hydrochloric in deer plasma by RP-HPLC,and to discuss pharmacokinetics of idazoxan hydrochloric in deer.Six clinical healthy Cervus nippon Temmincks(breed in a room) were injected with the idazoxan solution at the dose of 0.44 mg·kg-1.8 mL blood sample was taken from a jugular vein and plasma was separated for drug analysis using high liquid chromatography with ultraviolet detection.The results showed that the kinetics of idazoxan hydrochloric was fitted to one compartment model with first order absorption by route of administration.The main pharmacokinetic parameters were as follows: the half-lives of absorption(t1/2ka) and elimination(t1/2ke) were(2.09±0.34) and(13.18±0.24) min,respectively,area under the plasma drug concent ration-time curve from 0 to ∞(AUC) was(70±3.50)(μg·mL-1)·min,the peak plasma concent ration(Cmax) was(4.70±0.50) μg·mL-1,peaking at(12.46±0.12) min after dosing.The results indicated that idazoxan hydrochloric is characterized by rapid drug action,fast metabolism with little residue in the blood.
出处 《畜牧兽医学报》 CAS CSCD 北大核心 2011年第1期110-115,共6页 ACTA VETERINARIA ET ZOOTECHNICA SINICA
基金 黑龙江省博士后科研启动资助(LBH-Q07016)
关键词 盐酸苯噁唑 血药浓度 药代动力学 高效液相色谱 鹿 idazoxan hydrochloric plasma concentration pharmacokinetics RP-HPLC deer
  • 相关文献

参考文献23

  • 1BOUSQUET P, BRUBAN V, SCHANN S, et al. Participation of imidazoline receptors and alpha(2-) - adrenoceptors in the central hypotensive effects o5 imidazoline-like drugs[J]. Annals of the New York Academy of Sciences, 1999, 21(1): 272-278,.
  • 2CLARKE RW, HARRI J. RX 821002 as a tool for physiological investigation of alpha (2)-adreno -cep- tors[J]. CNS Drug Reviews, 2002, 8(2) : 177-192.
  • 3ERNSBERGER P R, MEELEY M P, MANN J, et al. Clonidlne binds to imidazole binding sites as well as α2-adrenoceptors in the ventrolateral medulla[J].Eur J Pharmacol, 1987, 134:1-14.
  • 4BRICCA G, DONTENWILL M, MOLINES A, et al. The imidazoline preferring receptor: binding studies in bovine, rat and human brainstem[J]. Eur J Pharmacol, 1989, 162: 1-9.
  • 5COUPRY I, ATLAS D, PODEVIN R A, et al. Imi- dazoline-guanidinium-reeeptive sites in renal proximal tubule: asymmetric distribution, regulation by cat- ions and interaction with an endogenous elonidine dis- placing substance[J]. Eur J Pharmacol, 1989, 252 293-299.
  • 6REGUNATHAN S, MEELEY M P, REIS D J. Ex- pression of nonadrenergic imidazoline sites in ehro- marlin cells and mitochondrial membranes of bovine adrenal medulla[J]. Biochem Pharmacol, 1993, 45 : 1667-1675.
  • 7MICHEL M C, INSEL P A. Are there multiple imi- dazoline binding sites? [ J]. Trends Pharmacol, 1989, 10: 342-344.
  • 8MICHEL M C, ERNSBERGER P L. Keeping an eye on the Ⅰ site: imidazoline preferring receptors[J]. Trends Pharmacol, 1992, 13: 369-370.
  • 9PARINI A, COUPRY I, GRAHAM R M, et al. Characterization of an imidazoline /guanidinium re- ceptive site distinct from the alpha2-adrenergic recep- tor[J]. JBiol Chem, 1989, 264: 11874-11878,.
  • 10TESSON F, PRIP-BUUS C, LEMOINE A, et al. SubceIiular distribution of imidazoline- Guanidinium- reeeptive sites in human and rabbit liver: major local- ization to the mitochondrial outer membrane[J]. J Biol Chem, 1991, 260:155-160.

二级参考文献10

  • 1Hou TD,Du JZ.Beta-endorphin suppresses release of thyrotropin-releasinghormone in rat hypothalamus during acute hypoxia exposure1[J].Acta Pharmacol Sin,2002,23(10):878-881.
  • 2Faletti AG,Mohn C,Farina M,et al.Interaction among beta-endorphin,nitric oxide and prostaglandins during ovulation in rats[J].Reproduction,2003,125(4):469-477.
  • 3Hitomi T,Masashi T,Hidekazu N,et al.Establishment of a specific radioimmunoassay for bovine interferon τ[J].Theriogenology,2005,63:1050-1060.
  • 4Han JS.Cholecystokin octapeptide:A negative feedback control mechanism for opioid analgesia[J].Prog Brain Res,1995,105:263-271.
  • 5Elisabet SV,Catharina L.Immunity and β-Endorphin concentrations in hypothalamus and plasma in rats with steroid-Induced polycystic ovaries:effect of low-frequency electroacupuncture[J].Biology of Reproduction,2004,(70):329-333.
  • 6Mostafa EM,Pierre B.Responsiveness of 5-HT1A and 5-HT2 receptorsin the rat orbitofrontal cortex after long-termserotonin reuptake inhibition[J].J Psychiatry Neurosci,2005,30(4):268-274.
  • 7赵荣材,张隆山.兽用镇静、镇痛、肌松药“静松灵”的研制和应用[J]中国农业科学,1981(04).
  • 8张立树,闫章年,李东郊,田慧英,马鹤雯,刘全,杨永胜,冯海华.xylazine+DHE对大鼠的麻醉作用及其对β-内啡肽含量的影响[J].中国兽医学报,2000,20(4):393-396. 被引量:5
  • 9孙忠人,王胜,李晓捷.针刺对实验性坐骨神经根压迫模型大鼠β—内啡肽的良性调节作用[J].中国中医药科技,2004,11(2):67-68. 被引量:22
  • 10尚建勋.动物化学保定药的发展概况[J].中国兽医科技,1992,22(1):19-21. 被引量:8

共引文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部